Myeloproliferative Neoplasms | Specialty

The OncLive Myeloproliferative Neoplasms condition center is a comprehensive resource for clinical news and expert insights on myeloproliferative neoplasms, including myelofibrosis, polycythemia vera, and essential thrombocythemia. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in myeloproliferative neoplasms.

Dr Gerds on Unmet Needs in Low-Risk Myelofibrosis

August 6th 2024

Aaron Gerds, MD, discusses clinical implications and areas of unmet need for patients with low- or intermediate-1–risk myelofibrosis.

Revisit Every OncLive On Air Episode From July 2024

July 31st 2024

In case you missed any, below is a recap of every OncLive On Air episode that aired in July 2024.

NCCN Recommends Imetelstat for Symptomatic Anemia in Lower-Risk MDS

July 31st 2024

The National Comprehensive Cancer Network has issued category 1 and 2A recommendations for imetelstat as therapy for symptomatic anemia in patients with lower-risk MDS.

Dr Watts on the Investigation of INCB057643 in Advanced Myelofibrosis and MPN

July 24th 2024

Justin M. Watts, MD, discusses the design and purpose of a phase 1 trial evaluating INCB057643 in myelofibrosis and other advanced myeloid neoplasms.

Dr Phillips on the Evolution of MDS Treatment

July 18th 2024

Tycel Phillips, MD, discusses the evolution of treatment for patients with myelodysplastic syndromes, highlighting the future of this treatment paradigm.

INCB057643 ± Ruxolitinib Shows Early Tolerability, Efficacy in Advanced Myelofibrosis

July 16th 2024

Justin M. Watts, MD, discusses phase 1 efficacy and safety data for the oral BET inhibitor INCB057643 in advanced myelofibrosis.

FDA Places Partial Clinical Hold on Phase 1 Trial of Seclidemstat Plus Azacitidine in MDS/CMML

July 16th 2024

The FDA has placed a partial clinical hold on a trial evaluating seclidemstat plus azacitidine in myelodysplastic syndromes or chronic myelomonocytic leukemia.

Pelabresib/Ruxolitinib Data Underscore Need for Novel End Points in Myelofibrosis Trials

July 15th 2024

Aaron Gerds, MD discusses updated efficacy findings from the prospective randomized phase 3 MANIFEST-2 trial.

Dr Klisovic on the Early Use of JAK Inhibitors in Younger Patients With Low-Risk Myelofibrosis

July 15th 2024

Rebecca Klisovic, MD, discusses the early use of JAK inhibitors to treat younger patients with low-risk, newly diagnosed myelofibrosis.

Dr Sekeres on Outcomes With Imetelstat in Transfusion-Dependent MDS

July 11th 2024

Mikkael A. Sekeres, MD, discusses a subgroup analysis of treatment with imetelstat in patients with low-to intermediate-1–risk myelodysplastic syndrome.

Dr Hunter on the Management Ruxolitinib-Associated AEs in Myelofibrosis

July 11th 2024

Anthony M. Hunter, MD, discusses challenges associated with ruxolitinib-based toxicities in patients with myelofibrosis.

Observational MOST Trial Reveals Progression Trends in Low-Risk Myelofibrosis

July 11th 2024

Aaron Gerds, MD, discusses progression data for patients with low- or intermediate-1–risk myelofibrosis in the MOST trial.

Subanalysis Supports Imetelstat for Transfusion-Dependent Low- to Intermediate-1–Risk MDS

July 10th 2024

Mikkael A. Sekeres, MD, discusses the FDA approval of imetelstat for patients with low- to intermediate-1–risk MDS, highlighting data from a subanalysis.

Phillips Discusses Past Progress and Previews the Future in Hematologic Cancers

July 10th 2024

Tycel Phillips, MD, highlights key takeaways in NHL, MDS, and myelofibrosis from an OncLive State of the Science Summit on hematology.

OncLive’s June Roundup of Key FDA Approvals in Oncology

July 3rd 2024

Here is your guide to the important regulatory decisions made by the FDA in June 2024.

Dr Hunter on the Evolution of Pathology in Myelofibrosis

July 2nd 2024

Anthony M. Hunter, MD, discusses the evolution of pathology in myelofibrosis based on outcomes from clinical trials.

Dr Sekeres on Outcomes from the ASTREON Trial in Low- to Intermediate-Risk MDS

June 26th 2024

Mikkael A. Sekeres, MD, discusses preliminary outcomes with oral azacitidine in lower-risk myelodysplastic syndromes, as reported in the ASTREON trial.

Momelotinib Wins Japanese Approval for Myelofibrosis

June 24th 2024

The Ministry of Health, Labour, and Welfare in Japan has approved momelotinib for use in patients with myelofibrosis.

Updated Safety and Efficacy Data From the Phase 3 MANIFEST-2 Study of Pelabresib in Combination With Ruxolitinib for JAK Inhibitor Treatment-Naïve Patients With Myelofibrosis

June 21st 2024

This is safety and efficacy update on the MANIFEST-2 trial (NCT02158858), a global, randomized, double-blind, active-control, phase 3 study using pelabresib in combination with ruxolitinib for JAK inhibitor treatment-naïve patients with myelofibrosis.

Dr Gerds on the Clinical Implications of Pelabresib Plus Ruxolitinib in Myelofibrosis

June 14th 2024

Aaron Gerds, MD, discusses the clinical implications of outcomes with pelabresib plus ruxolitinib therapy in JAK inhibitor–naive myelofibrosis.

NEXT PAGE
PREVIOUS PAGE